Up Close with Mosunetuzumab
Last Updated: May 16, 2025
Discover more about mosunetuzumab-axgb (LUNSUMIO™).
Related Resources:
PQI
PQI: Initiating Mosunetuzumab-axgb (Lunsumio) in Relapsed/Refractory Follicular Lymphoma
Last Updated: 07/17/2025
Perspectives
OncolyticsToday: The Bispecific Antibody Revolution
Author: KELLY BRUNK
Last Updated: 04/01/2024
Find Similar Resources:
Immunotherapy
Immunotherapy
Immunotherapy
Immunotherapy
Overview of BTCEs: Comparison of Bispecific T-Cell Engagers (BTCEs)
Last Updated: 02/19/2026
Example SOPs and Documents: Transitioning Patients on Bispecific T-Cell Engagers Between Care Settings
Last Updated: 07/01/2025
Example SOPs and Documents: Bispecific T-cell Engager Billing Procedure
Last Updated: 07/01/2025
Up Close with Linvoseltamab
Last Updated: 05/16/2025
PQI
PQI Podcast
PQI Podcast
Patient Education Sheet
PQI: Belantamab Mafodotin (Blenrep) for the Management of Multiple Myeloma
Last Updated: 04/03/2026
S10 E7: Scaling Hope: The Future of Cell Therapy Access
Last Updated: 04/06/2026
S10 E6: Modern Antibody-drug conjugates and New CINV Challenges
Last Updated: 04/06/2026
Pembrolizumab and GVD
Last Updated: 03/19/2026